Valeant (VRX) failed in its attempt to snag Cephalon (CEPH), but the company is hardly nursing...

|By:, SA News Editor

Valeant (VRX) failed in its attempt to snag Cephalon (CEPH), but the company is hardly nursing its wounds. CEO Michael Pearson says Valeant is already in talks with other potential takeover targets and has the resources to pursue even larger deals than Cephalon would have been.